Free Trial
→ He Called Nvidia at $1.10. Now, He Says THIS Stock Will… (From The Oxford Club) (Ad)tc pixel Free LLY Stock Alerts

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company logo
$736.26 +1.08 (+0.15%)
Closing price 03:59 PM Eastern
Extended Trading
$736.34 +0.08 (+0.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 24 Analyst Ratings
Sell
0
Hold
9
Buy
15

Based on 24 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 9 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$950.17
29.05% Upside
According to the 24 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $950.17. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 29.05% from the current price of $736.27.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

TypeCurrent Forecast
9/3/24 to 9/3/25		1 Month Ago
8/4/24 to 8/4/25		3 Months Ago
6/5/24 to 6/5/25		1 Year Ago
9/4/23 to 9/3/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
16 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
Hold
9 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$950.17$1,012.56$1,011.37$961.76
Forecasted Upside29.05% Upside31.89% Upside32.18% Upside0.55% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside29.20% Upside15,435.49% Upside11.66% Upside
News Sentiment Rating
Positive News

See Recent LLY News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/27/2025HSBC
2 of 5 stars		Rajesh Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeReduce ➝ Hold$675.00 ➝ $700.00-4.75%
8/27/2025Hsbc Global Res
5 of 5 stars		 UpgradeModerate Sell ➝ Hold
8/17/2025Daiwa Capital Markets
2 of 5 stars		Narumi Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Neutral$700.00-0.22%
8/17/2025Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeStrong-Buy ➝ Hold
8/14/2025DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Strong-Buy
8/13/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetOverweight ➝ Overweight$975.00 ➝ $825.00+25.02%
8/13/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Seamus Fernandez
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$942.00 ➝ $875.00+35.19%
8/11/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		James Shin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$1,010.00 ➝ $900.00+40.51%
8/8/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$1,050.00 ➝ $895.00+42.63%
8/7/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeStrong-Buy ➝ Hold
8/7/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Market Perform
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform ➝ Market Perform$715.00+11.07%
7/10/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$1,133.00 ➝ $1,135.00+43.19%
6/5/2025Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Hold
5/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy$892.00 ➝ $888.00+20.24%
2/3/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00+27.51%
1/28/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00+47.25%
1/16/2025Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Kerry Holford
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target$970.00+10.97%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$997.00+24.17%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$1,000.00+27.23%
11/4/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Baker
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold
10/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00+16.30%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$1,100.00+20.04%
9/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,100.00+17.67%
9/5/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold
8/9/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$1,001.00 ➝ $1,101.00+30.36%
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$994.00 ➝ $1,015.00+12.98%
5/14/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$770.00 ➝ $840.00+11.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:39 PM ET.


Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 2, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • The current stock price is around $732, reflecting a strong market position and investor confidence in the company's growth potential.
  • Eli Lilly and Co reported impressive quarterly earnings, with earnings per share (EPS) significantly exceeding analyst expectations, indicating robust financial health.
  • The company has shown a remarkable year-over-year revenue growth of over 37%, suggesting strong demand for its products and effective business strategies.
  • With a net margin of nearly 26%, Eli Lilly and Co demonstrates efficient cost management and profitability, which can lead to higher returns for investors.
  • The firm has a solid dividend yield of 0.8%, providing a steady income stream for investors, which is particularly attractive in volatile markets.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • Insider ownership is relatively low at 0.14%, which may indicate a lack of confidence from those closest to the company.
  • The company's debt-to-equity ratio is 1.86, suggesting a higher reliance on debt financing, which can pose risks in economic downturns.
  • Recent stock price fluctuations indicate volatility, which could lead to potential losses for investors if market conditions change.
  • While the company has strong revenue growth, it may face increasing competition in the pharmaceutical sector, which could impact future profitability.
  • The price-to-earnings (PE) ratio of 47.87 is relatively high, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.

LLY Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $950.17, with a high forecast of $1,190.00 and a low forecast of $700.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 9 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 29.05% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 4 downgrades and 3 upgrades by analysts.

Analysts like Eli Lilly and Company less than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.67 while the average consensus rating score for "medical" companies is 2.78. Learn more on how LLY compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:LLY) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners
How “Trump’s New Dollar” Could Impact Your Wealth
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
This Coin Could Explode, and it’s Hiding in Plain Sight!
The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...
Crypto 101 Media | Sponsoredtc pixel
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
The Orphaned Well Crisis Hidden Across America
Across the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...
The Tomorrow Investor | Sponsoredtc pixel